In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

Recent research suggests lecanemab may be less effective in females, raising important questions for future Alzheimer’s drug ...

The anti-amyloid therapy gantenerumab lowered the chances for developing Alzheimer’s-related dementia in people at high risk for the disease, according to a small study conducted by the Knight Family ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...